9
Copyright © 2009 Driven Forward Aspirin Inc. Aspirin Inc. The Cure For The Common Headache The Cure For The Common Headache Investor Presentation Investor Presentation

Aspirin Inc

Embed Size (px)

DESCRIPTION

Sample Investor Presentation.

Citation preview

Page 1: Aspirin Inc

Copyright © 2009 Driven Forward

Aspirin Inc.Aspirin Inc.The Cure For The Common HeadacheThe Cure For The Common Headache

Investor PresentationInvestor Presentation

Page 2: Aspirin Inc

Copyright © 2009 Driven Forward

What if your head hurt so badWhat if your head hurt so bad

• you couldn’t seeyou couldn’t see

• you couldn’t driveyou couldn’t drive

• you couldn’t workyou couldn’t work

• You couldn't care for You couldn't care for your childrenyour children

• you couldn’t function you couldn’t function

45 million Americans suffer 45 million Americans suffer chronicchronic headaches headaches

Page 3: Aspirin Inc

Copyright © 2009 Driven Forward

What if a pill could make the pain What if a pill could make the pain go way in minutes?go way in minutes?

• Relief is just Relief is just seconds awayseconds away

• 90% efficacy90% efficacy

• Proprietary Proprietary Patented Patented TechnologyTechnology

What would 45 million people pay for instant relief?What would 45 million people pay for instant relief?

Page 4: Aspirin Inc

Copyright © 2009 Driven Forward

Conservative Revenue Projections

$0

$20

$40

$60

$80

$100

$120

$140

$160

2009 2010 2011 2012 2013

Enormous MarketEnormous Market

45M Americans x 2 headaches per month45M Americans x 2 headaches per month1B Headaches per year1B Headaches per year$2B Per Year Market @ $2.00 per pill $2B Per Year Market @ $2.00 per pill

Page 5: Aspirin Inc

Copyright © 2009 Driven Forward

Management TeamManagement Team

• CEO – Mary SmithCEO – Mary Smith– Founder/CEO BigProfitableCo acquired by EvenBiggerCo for Founder/CEO BigProfitableCo acquired by EvenBiggerCo for

a 12X ROI to Investorsa 12X ROI to Investors– University of Maryland RH Smith MBAUniversity of Maryland RH Smith MBA

• CFO – Bob AndweveCFO – Bob Andweve– CFO Big Pharma R&D DivisionCFO Big Pharma R&D Division– Harvard MBAHarvard MBA

• VP Sales & Marketing – Sally CansellVP Sales & Marketing – Sally Cansell– Grew Bandaid Inc Pharma Div Sales from $0 to $40M in 4 Grew Bandaid Inc Pharma Div Sales from $0 to $40M in 4

yearsyears– Once sold ice to an InuitOnce sold ice to an Inuit

• COO– Tom CandoCOO– Tom Cando– 12 years as Manufacturing Head of Placebo Pills Inc12 years as Manufacturing Head of Placebo Pills Inc

Been There, Done ThatBeen There, Done That

Page 6: Aspirin Inc

Copyright © 2009 Driven Forward

Go To MarketGo To Market

• Scalable contract manufacturing Scalable contract manufacturing agreement in placeagreement in place

• Sales Team with strong Sales Team with strong relationships with 5 of the top 8 relationships with 5 of the top 8 drug storesdrug stores

• In negotiations with Asian and In negotiations with Asian and European distributors European distributors

Ready For SuccessReady For Success

Page 7: Aspirin Inc

Copyright © 2009 Driven Forward

CompetitionCompetition

SpeedSpeed FastFastSlowSlow

AspirinAspirin

Effe

ctiv

enes

sE

ffect

iven

ess

Hig

hH

igh

Low

Low

Hammer

Coffee

Tea

Page 8: Aspirin Inc

Copyright © 2009 Driven Forward

FinancialsFinancials(US Dollars In Millions)(US Dollars In Millions)

-$10

$10

$30

$50

$70

$90

$110

$130

2009 2010 2011 2012 2013

SalesEBITA

EBITA – Earnings before Investments, Taxes and Amortization

Page 9: Aspirin Inc

Copyright © 2009 Driven Forward

Funding and FinanceFunding and Finance

• $5 Million Raise$5 Million Raise– ““A” RoundA” Round– No Additional Rounds AnticipatedNo Additional Rounds Anticipated

• Use of FundsUse of Funds– $1 Million for Intellectual Property Protection$1 Million for Intellectual Property Protection– $2 Million for US Sales and Marketing$2 Million for US Sales and Marketing– $1 Million for International Distribution$1 Million for International Distribution– $1 Million for Inventory$1 Million for Inventory

• Anticipated IPO or Acquisition in 4 yearsAnticipated IPO or Acquisition in 4 years

Target $100+ Million or 20X Return Target $100+ Million or 20X Return